Reportstack

PharmaPoint: Postmenopausal Vaginal Atrophy - Spain Drug Forecast and Market Analysis to 2022

 
Repost This

Naperville, IL -- (SBWIRE) -- 12/05/2013 -- Reportstack, provider of premium market research reports announces the addition of PharmaPoint: Postmenopausal Vaginal Atrophy - Spain Drug Forecast and Market Analysis to 2022 market report to its offering
PharmaPoint: Postmenopausal Vaginal Atrophy - Spain Drug Forecast and Market Analysis to 2022

Summary

Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade, it is expected to undergo a considerable change between 2012 and 2022. This market has historically had a large untreated population due to: low diagnosis rates, safety issues with the existing therapies, and poor patient compliance. Since the mainstay estrogen-based therapies are associated with causing elevated risk for breast cancer, endometrial cancer, and stroke, many women go untreated.

Historically, there exists a high level of brand loyalty among Spanish patients. As a result, this market will see much lower generic erosion than the US and German markets. Spains PVA market will face temperate generic erosion, as Tevas Colpotrofin cream and Colpotrofin vaginal tablet lose patent protection in 2015. Late in the forecast period, this market will see Vagifems loss of patent exclusivity in 2020.

Scope

- Overview of PVA including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Spain from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Spain PVA market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for PVA
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Spain

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/147107/pharmapoint-postmenopausal-vaginal-atrophy-spain-drug-forecast-and-market-analysis-to-2022.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###